Lamivudine
Back to searchMolecule Structure
Scientific Name
Lamivudine
Description of the Drug
Lamivudine is a reverse transcriptase inhibitor used to treat HIV and hepatitis B infections.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00709
http://www.drugbank.ca/drugs/DB00709
Brand Name(s)
Epivir, Epivir-hbv, Lamivudine, Zeffix
Company Owner(s)
Cipla Ltd, Glaxosmithkline, Macleods Pharmaceuticals Ltd, Laurus Labs Ltd, Mylan Pharmaceuticals Inc, Zydus Pharmaceuticals Usa Inc, Merck Sharp And Dohme Corp A Sub Of Merck And Co Inc, Micro Labs Ltd, Anda Repository Llc, Pharmacare Ltd
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA polymerase/reverse transcriptase | SINGLE PROTEIN | INHIBITOR | CHEMBL2362994 |
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2363048 |
Human immunodeficiency virus type 1 reverse transcriptase | SINGLE PROTEIN | INHIBITOR | CHEMBL247 |
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2363046 |
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2363047 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL109675 | ||
PharmGKB | PA450163 | ||
Human Metabolome Database | HMDB0014847 | ||
DrugBank | DB00709 | ||
PubChem: Thomson Pharma | 14798125 | 15121620 | |
PubChem | 60825 | ||
Mcule | MCULE-8483986532 | MCULE-2096184994 | |
NMRShiftDB | 70000621 | ||
LINCS | LSM-5215 | ||
Nikkaji | J457.051K | ||
PDBe | 3TC | ||
BindingDB | 50366817 | ||
DrugCentral | 1539 | ||
Brenda | 229605 | 229604 | 6246 |
ChemicalBook | CB1290608 | ||
rxnorm | LAMIVUDINE | EPIVIR | |
PubChem: Drugs of the Future | 12014700 | ||
KEGG Ligand | C07065 | ||
ChEBI | 63577 | ||
ZINC | ZINC000000012346 |